Received Sep 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 2553X | — |
Twinrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 73-year-old male patient who received HAB (Twinrix) (batch number 2553X, expiry date 25-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose 07-MAR-2025). On 28-AUG-2025, the patient received the 2nd dose of Twinrix. On 28-AUG-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-AUG-2025 The pharmacist wanted to know when to administer the third dose of Twinrix after the patient received a late second dose according to the schedule. First dose was administered on 07th March 2025 and the second on 28th August 2025 (174 days apart) which led to lengthening of vaccination schedule. The vaccine administration facility was the same as primary reporter.